A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

This study is a multicenter, open label, single-arm phase I/II clinical trial of WSD0922-FU for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed with thrid-generation EGFR-TKI .

Trial Details

NCT ID
NCT06631989
Phase
PHASE1 / PHASE2
Sponsor
Wayshine Biopharm, Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • WSD0922-FU
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Age 18-75 years old (including the threshold value), gender is not limited;
  • Locally advanced or metastatic NSCLC confirmed by pathology;
  • Patients who have been genetically tested to carry EGFR sensitive mutations;
  • Blood samples must be provided for testing and must be taken during or after disease progression following the last EGFR TKI inhibitor treatment;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →